EXCIVA GmbH

EXCIVA GmbH is a clinical-stage biopharmaceutical company based in Heidelberg, Germany, founded in 2016.

The company specializes in biotechnology research aimed at developing therapies for Alzheimer's disease and other neuropsychiatric conditions. With a small team of 2-10 employees, EXCIVA focuses on the symptomatic management of dementia-related issues, including agitation, aggression, and depression. The company's lead program, EXV-802 (also known as Deraphan), is currently in a Phase 2/3 clinical trial called SERENADA, targeting agitation in Alzheimer's dementia. This program has received Fast Track designation from the US FDA. EXCIVA emphasizes rigorous clinical trials and collaborations to advance its research and aims to enhance patient independence while reducing caregiver distress. The company recently secured €51 million ($59 million) in a Series B financing round and is part of the EQT portfolio through the LSP Dementia Fund.